Navigation Links
Approval Of Boston Scientific's Watchman Device Will Support Rapid Growth In The Global Heart Defect Closure Device Market
Date:6/12/2013

TORONTO, June 12, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's WATCHMAN device will drive rapid growth in the market for global heart defect closure devices.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

Although a number of epicardial left arterial appendage (LAA) closure devices are available worldwide, the WATCHMAN device will represent the first FDA-approved endocardial LAA device when it enters the market in the latter half of 2013. Approval is more difficult to obtain for endocardial devices because they are placed directly inside the LAA opening of the heart, whereas epicardial devices function from outside of the heart.

"Endocardial LAA closure devices have huge global market potential," said MRG Senior Analyst Sean Messenger. "These devices will expand the eligible patient pool for LAA closure because they will be approved for stand-alone use in the US, as they are in Europe. By contrast, the majority of epicardial devices are only approved for concomitant use when patients are undergoing open cardiac surgery for another condition. Physicians are also familiar with endocardial devices given that interventional cardiologists have been using very similar devices for many years."

Market growth will be particularly strong in the US, where clinical trial results from the PROTECT-AF and PREVAIL studies will support device approval and encourage physician adoption of the WATCHMAN device. FDA approval is also highly regarded in Europe, and as a result, the WATCHMAN device will see strong uptake in this market as well. The device will not enter the Japanese market until it has been well-established in the US and Europe, although market growth is expected to be strong once endocardial LAA devices enter this space.

St. Jude Medical, the current global leader of the heart defect closure device market, is also expected to eventually enter the endocardial LAA closure device segment; the company recently began a US-based trial for a device in this space. This is not expected to occur for some time, however, and Boston Scientific will enjoy a first-to-market advantage, monopolizing this market for a number of years.   

Millennium Research Group's Global Markets for Heart Defect Closure Devices 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for congenital heart defect, patent foramen ovale (PFO) and LAA closure devices in the United States, France, Germany, Italy, the United Kingdom and Japan.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
2. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
3. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
4. Cochlear Americas Receives FDA Approval for the First and Only Ear Level Accessory for Waterproof Hearing with Cochlear Implants
5. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
6. ReproCELL Inc. Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth
7. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
8. Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. MiEs PET SCINTRON Receives FDA Approval
11. TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):